OMERS ADMINISTRATION Corp Buys Shares of 41,500 Stoke Therapeutics, Inc. $STOK

OMERS ADMINISTRATION Corp purchased a new position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) in the first quarter, Holdings Channel reports. The fund purchased 41,500 shares of the company’s stock, valued at approximately $1,351,000.

Several other institutional investors and hedge funds also recently modified their holdings of STOK. Kestra Advisory Services LLC acquired a new position in shares of Stoke Therapeutics during the fourth quarter valued at $26,000. KBC Group NV acquired a new stake in Stoke Therapeutics in the first quarter worth about $36,000. Harbour Investments Inc. lifted its holdings in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after purchasing an additional 898 shares during the period. BNP Paribas Financial Markets grew its position in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after buying an additional 1,668 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after buying an additional 3,591 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have commented on STOK. BTIG Research restated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research report on Monday, May 11th. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, The Goldman Sachs Group began coverage on shares of Stoke Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $44.00 price objective on the stock. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.00.

Stoke Therapeutics Stock Up 0.3%

Shares of STOK stock opened at $29.48 on Thursday. The stock has a 50-day simple moving average of $30.38 and a 200 day simple moving average of $32.03. Stoke Therapeutics, Inc. has a fifty-two week low of $12.40 and a fifty-two week high of $40.22. The stock has a market capitalization of $1.84 billion, a P/E ratio of -10.49 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The firm had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.48 million. On average, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

Insider Activity

In related news, General Counsel Jonathan Allan sold 1,457 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the sale, the general counsel directly owned 18,086 shares of the company’s stock, valued at $541,675.70. This represents a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the sale, the insider owned 34,826 shares of the company’s stock, valued at $1,064,979.08. The trade was a 4.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 9.60% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.